title: Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study.
abstract: OBJECTIVE
  The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1) level as a predictor of future acute coronary events in patients with chronic coronary heart disease (CHD).
  
  
  BACKGROUND
  Increased sICAM-1 concentration has been shown to be associated with the incidence of CHD in healthy persons. Its significance in patients with CHD has been scarcely investigated.
  
  
  METHODS
  We designed a prospective, nested case-control study. Sera were collected from patients with CHD enrolled in a secondary prevention trial that evaluated the efficacy of bezafibrate in reducing coronary events. We measured baseline sICAM-1 concentration in the sera of patients who developed subsequent cardiovascular events (cases: n = 136) during follow-up (mean: 6.2 years) and in age- and gender-matched controls (without events: n = 136).
  
  
  RESULTS
  Baseline serum concentrations of sICAM-1 were significantly higher in cases versus controls (375 vs. 350 ng/ml; p < 0.05). Each 100 ng/ml increase in sICAM-1 concentration was associated with 1.27 (95% confidence interval [CI]: 1.00 to 1.63) higher relative odds of coronary events. Soluble ICAM-1 concentration in the highest quartile (>394 ng/ml) was associated with significantly higher odds of coronary events (compared with the lowest quartile), even after multivariate adjustment (2.31, 95% CI: 1.02 to 5.50). After adding fibrinogen and total white blood cell count to the multivariate model, the relative odds were 2.12 (95% CI: 0.88 to 5.35) and 2.70 (95% CI: 1.10 to 7.05), respectively.
  
  
  CONCLUSIONS
  Elevated sICAM-1 concentration in CHD patients is associated with increased risk of future coronary events independent of other traditional risk factors.
authors.affiliation: Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. motih@netvision.net.il
authors.forename: Moti
authors.initials: M
authors.lastname: Haim
authors.forename: David
authors.initials: D
authors.lastname: Tanne
authors.forename: Valentina
authors.initials: V
authors.lastname: Boyko
authors.forename: Tamar
authors.initials: T
authors.lastname: Reshef
authors.forename: Uri
authors.initials: U
authors.lastname: Goldbourt
authors.forename: Jonathan
authors.initials: J
authors.lastname: Leor
authors.forename: Yoseph A
authors.initials: YA
authors.lastname: Mekori
authors.forename: Solomon
authors.initials: S
authors.lastname: Behar
mesh_terms: D001629:Bezafibrate / Q000627:therapeutic use*; D016022:Case-Control Studies; D003327:Coronary Disease / Q000097:blood* / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D011446:Prospective Studies; D018570:Risk Assessment; D013997:Time Factors
chemical_list: D000960:Hypolipidemic Agents; D018799:Intercellular Adhesion Molecule-1; D001629:Bezafibrate